NCT05815459 (MOOD) is a clinical trial of OCOsense in Major Depressive Disorder, sponsored by Emteq Ltd.

Who is sponsoring NCT05815459?

NCT05815459 is sponsored by Emteq Ltd.

What drugs are being tested in NCT05815459?

Interventions in NCT05815459: OCOsense.

What condition does NCT05815459 study?

NCT05815459 studies Major Depressive Disorder, Major Depressive Episode, Bipolar Disorder.

Is NCT05815459 still recruiting?

NCT05815459 is currently completed. Last updated 9 May 2023.

Last reviewed 2023-05-09 · How we verify

NCT05815459: MOOD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mobile Observation Of Depression

Completed Last updated 9 May 2023

What this trial tests

trial testing OCOsense in Major Depressive Disorder in 84 participants. Completed in 1 February 2023.

Timeline

15 July 2022

Primary endpoint
1 February 2023

1 February 2023

Quick facts

Lead sponsor	Emteq Ltd
Status	Completed
Study type	OBSERVATIONAL
Enrollment	84
Start date	15 July 2022
Primary completion	1 February 2023
Estimated completion	1 February 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

OCOsense

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →
Major Depressive Episode — all drugs for Major Depressive Episode →
Bipolar Disorder — all drugs for Bipolar Disorder →

Sponsor

Emteq Ltd

Who can join

Adults 18 to 40, any sex, with Major Depressive Disorder or Major Depressive Episode. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this project is to test if OCOsense glasses can function as a digital phenotyping tool derived from behavioural and physiological signals related to facial expression and motion recorded using the glasses.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Optomyography-based sensing of facial expression derived arousal and valence in adults with depression.
Broulidakis MJ, Kiprijanovska I, Severs L, Stankoski S, et al · · 2023 · cited 2× · PMID 37614653 · DOI 10.3389/fpsyt.2023.1232433

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05815459 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emteq Ltd
Last refreshed: 9 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05815459.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing